An FXR agonist, obeticholic acid, is the first molecule to deliver a statistically significant improvement in one of the FDA’s surrogate endpoints for accelerated approval of a treatment for NASH. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.